文献速递膀胱癌与上尿路尿路上皮癌

荧光原位杂交预测中高危非肌层浸润性膀胱癌卡介苗灌注后复发:个体患者数据系统评价与荟萃分析

The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.
PubMed 文献 · J Urol · 2019-09-24

该系统评价与个体患者数据荟萃分析纳入4项前瞻性观察研究共422例患者,最终分析408例,中位随访18.8个月。结果显示卡介苗灌注后FISH阳性与复发风险升高相关,6周、3个月、6个月的复发HR分别为2.23、3.70、23.44;推荐在经尿道膀胱肿瘤电切术后3个月进行FISH检测以辅助风险分层和咨询。

要点

  • 卡介苗灌注前FISH阳性与复发风险无显著相关(HR 1.20,95%CI 0.81-1.79)。
  • 灌注后6周、3个月、6个月FISH阳性者复发风险分别升高至HR 2.23、3.70、23.44。
  • 推荐在经尿道膀胱肿瘤电切术后3个月行FISH检测,此时HR的95%CI最窄。

核心结论

  • 卡介苗灌注后FISH阳性与肿瘤复发风险升高相关,可辅助风险分层和患者咨询。
  • 基于HR及最窄95%CI,FISH首选检测时机为经尿道膀胱肿瘤电切术后3个月。

研究设计与样本

  • 系统评价与个体患者数据荟萃分析,检索MEDLINE、Embase和Cochrane Library。
  • 纳入4项前瞻性观察研究,共获取422例患者个体数据,最终分析408例,中位随访18.8个月。
  • 采用两阶段个体患者数据荟萃分析评估FISH对卡介苗诱导治疗后肿瘤复发的预测价值。

主要发现

  • 卡介苗灌注前(time 0)FISH阳性者复发HR为1.20(95%CI 0.81-1.79)。
  • 卡介苗灌注后6周(time 1)FISH阳性者复发HR为2.23(95%CI 1.31-3.62)。
  • 卡介苗灌注后3个月(time 2)FISH阳性者复发HR为3.70(95%CI 2.34-5.83)。
  • 卡介苗灌注后6个月(time 3)FISH阳性者复发HR为23.44(95%CI 5.26-104.49)。

临床怎么用

  • 对中高危非肌层浸润性膀胱癌接受卡介苗治疗的患者,可在经尿道膀胱肿瘤电切术后3个月行FISH检测以辅助风险分层。
  • FISH阳性结果可用于咨询患者复发风险,并帮助识别诱导治疗失败、需考虑临床试验或调整治疗策略的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to assess the value of fluorescence in situ hybridization to predict early recurrence in patients with nonmuscle invasive bladder cancer at intermediate and high risk treated with bacillus Calmette-Guérin. MATERIALS AND METHODS: We performed a systematic review using MEDLINE®, Embase® and the Cochrane Library. Individual patient data from prospective observational studies of fluorescence in situ hybridization in patients treated with bacillus Calmette-Guérin were included. A 2-stage individual patient data meta-analysis was done to assess the value of fluorescence in situ hybridization to predict tumor recurrence after bacillus Calmette-Guérin induction therapy. RESULTS: From a total of 4 studies we obtained individual data on 422 patients, of whom 408 with a median followup of 18.8 months were included in the final analysis. When fluorescence in situ hybridization was positive, the recurrence HR was 1.20 (95% CI 0.81-1.79) before bacillus Calmette-Guérin (time 0), 2.23 (95% CI 1.31-3.62) at 6 weeks (time 1), 3.70 (95% CI 2.34-5.83) at 3 months (time 2) and 23.44 (95% CI 5.26-104.49) at 6 months (time 3). CONCLUSIONS: A positive fluorescence in situ hybridization test after bacillus Calmette-Guérin correlated with higher risk of recurrent tumor. Fluorescence in situ hybridization could aid urologists in risk stratifying and counseling patients. Based on the HR and the narrowest CI the preferred timing of fluorescence in situ hybridization is 3 months after transurethral resection of bladder tumor. This is also in time for patients in whom induction therapy fails to enter clinical trials or change the treatment strategy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Liem EIML, Oddens JR, Vernooij RWM, et al. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol. 2019. PMID: 31549936. doi:10.1097/JU.0000000000000566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。